CDH1 and gastric cancer: Moreover, it was recently reported that among the four potential N-glycosylation sites on the extracellular domain of E-cadherin, Asn-554 is the key N-glycosylation site that, within a gastric cancer context, is selectively modified with the deleterious β1,6 GlcNAc branched N-glycans, and directly affects E-cadherin functions [21].